Novartis AG and others v Focus pharmaceuticals Ltd and others; Novartis AG and others v Teva UK Ltd [2015] EWHC 1068 (Pat), [2015] All ER (D) 233 (Apr)
The Patents Court considered a claim for infringement of European Patent (UK) No 2 292 219 directed to the use of rivastigmine for use in the treatment of Alzheimer’s disease wherein the rivastigmine was administered by a transdermal therapeutic system. The court held that the patent was invalid on the ground of added matter and since the claimed invention lacked an inventive step over a previous patent.
